Centrient Pharmaceuticals joins Almirall’s growing innovation hub in Barcelona

Contributed by: Business Wire

Logo

Images

Almirall R&D site at Sant Feliu de Llobregat (Barcelona, Spain) (Photo: Business Wire)

Business Wire embedded0

Tags

Health

Clinical Trials

Research

Pharmaceutical

Science

Biotechnology

Centrient Pharmaceuticals

More Like This

From left upper row, to right: Marc Soriano, R&D Project Portfolio and Partnership, Lidia Martín, General Manager of Almirall Iberia, Antonio Gallardo, Jorge Gallardo, Dr. Karl Ziegelbauer, Chief Scientific Officer of Almirall, Meritxell Granell, Director of Institutional Relations, Raquel Yotti, PERTE Commissioner for Vanguard Health, Olga Pané, Consellera de Salut, Lourdes Borrell, Mayoress of Sant Feliu de Llobregat, Salvador Illa, President of the Generalitat de Catalunya, Carlos Gallardo, CEO and President of Almirall, Juan Cruz Cigudosa, Secretary of State for Science, Innovation and Universities, Núria Montserrat, Consellera de Recerca i Universitats, and Jaume Baró, Secretary for Business and Competitiveness of the Department of Business and Employment. (Photo: Business Wire)

Almirall Launches The Hive, Creating a Novel Collaborative Innovation Hub to Advance Life Sciences and Healthcare

Almirall HQ in Barcelona (Photo: Business Wire)

Almirall at the JPMorgan Conference - Entering a New Era of Sustained Growth

Almirall HQ in Barcelona (Photo: Business Wire)

Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical Dermatology Pipeline

PR Newswire associated0

Alamar Biosciences Establishes European Headquarters and Distribution Center in Milan, Italy

Rejuveron Life Sciences AG Rebrands as Centenara Labs AG and Provides Latest Clinical Updates

Almirall photovoltaic installation in HQ Barcelona (Photo: Business Wire)

Almirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030

Almirall HQ in Barcelona (Photo: Business Wire)

Almirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth

Ardena Signs Agreement to Expand US Footprint with the Acquisition of Advanced Drug Product Manufacturing Facility from Catalent